Mazzo David J 4

4 · LISATA THERAPEUTICS, INC. · Filed Jan 13, 2026

Form 4

Period: 2026-01-09

DirectorPresident & CEO

Transactions

Award
Common Stock
[F1][F2]
2026-01-09+81,000→ 352,986 total
Tax Payment
Common Stock
[F3][F2]
2026-01-09$1.97/sh−10,503$20,691→ 342,483 total
Tax Payment
Common Stock
[F3][F2]
2026-01-09$1.97/sh−10,515$20,715→ 331,968 total
Tax Payment
Common Stock
[F3][F2]
2026-01-09$1.97/sh−12,224$24,081→ 319,744 total
Tax Payment
Common Stock
[F3][F2]
2026-01-09$1.97/sh−7,854$15,472→ 311,890 total
Award
Stock Option (Right to Buy)
[F4]
2026-01-09+40,000→ 40,000 total
Exercise: $1.97From: 2026-01-09Exp: 2036-01-09→ Common Stock (40,000 underlying)

Footnotes (4)

[F1]Represents 81,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.
[F2]Includes 124,750 unvested restricted stock.
[F3]Shares withheld as payment of a tax liability on vesting of restricted stock.
[F4]One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date.

Signature

James Nisco, Attorney-in-Fact for David J. Mazzo|2026-01-13

Documents

1 file